search
Back to results

Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients

Primary Purpose

Nosocomial Pneumonia, Healthcare-Associated Pneumonia, Aspiration Pneumonia

Status
Completed
Phase
Phase 4
Locations
India
Study Type
Interventional
Intervention
Chlorhexidine gluconate
Potassium permanganate
Sponsored by
King Edward Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Nosocomial Pneumonia focused on measuring oropharyngeal cleansing, oral decontamination, oropharyngeal bacterial flora, oropharyngeal colonization, critical illness, mechanical ventilation, tracheal intubation, prophylaxis

Eligibility Criteria

13 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients admitted to the medical intensive care unit and are expected to stay in ICU for > 48 hours

Exclusion Criteria:

  • Pregnant women
  • Patients with nosocomial pneumonia at time of ICU admission
  • Patients with community-acquired pneumonia at time of ICU admission
  • Patients in whom oropharyngeal cleansing is contra-indicated

Sites / Locations

  • Medical-Neuro Intensive Care Unit, K E M Hospital, Parel

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1

2

Arm Description

Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate

Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate

Outcomes

Primary Outcome Measures

Development of nosocomial pneumonia

Secondary Outcome Measures

In-hospital mortality
Length of ICU stay (days)

Full Information

First Posted
January 16, 2008
Last Updated
January 24, 2008
Sponsor
King Edward Memorial Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00610324
Brief Title
Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients
Official Title
Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients: an Open-Labelled Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2008
Overall Recruitment Status
Completed
Study Start Date
May 2004 (undefined)
Primary Completion Date
October 2007 (Actual)
Study Completion Date
December 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
King Edward Memorial Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Oropharyngeal bacteria play an important role in the pathogenesis of nosocomial pneumonia in critically ill patients. Oral cleansing with chlorhexidine has been shown to decrease incidence of pneumonia in patients undergoing open heart surgery. Its role in critically ill general ICU patients is not yet proven. The present study proposes to study the effectiveness of twice-daily oral cleansing with 0.2% chlorhexidine solution on the incidence of nosocomial pneumonia in ICU patients admitted to a single intensive care unit of an Indian public hospital
Detailed Description
Nosocomial pneumonia is common in intensive care units (ICU) patients and is associated with increase in mortality rates by 24% to 76% in various studies. Interventions that effectively prevent nosocomial pneumonia are strategically important in order to reduce morbidity, mortality and healthcare costs. Colonization of the pharynx has been implicated as the reservoirs for pathogens causing nosocomial pneumonia and interventions like selective digestive decontamination have been tried to control this source of infection. Recently, colonization of the dental plaque by aerobic organisms with subsequent aspiration into the lower respiratory tract has received attention. Previous smaller studies using antiseptic agents to sterilize dental plaques in patients at risk of pneumonia have shown conflicting results. The present study aims to determine whether twice daily oral cleansing with 0.2% chlorhexidine reduces the incidence of nosocomial pneumonia in patients staying in the ICU for >48 hours. After obtaining informed consent, subjects would be randomized to treatment with either 0.2% chlorhexidine gluconate (CHG) solution or 0.01% potassium permanganate solution (PP) (Control Group), as per the protocol approved by the Institutional Ethics Committee. At baseline, the parameters which would be noted are: age, sex, surgical or non-surgical status, immunosuppression, chronic ailments, smoking and alcohol consumption, Glasgow coma scale score (GCS), laboratory parameters and blood gas analysis. All subjects would be followed up daily and the GCS, presence of nasogastric tube (feeds), endotracheal tube, tracheostomy, ventilator, central venous and urinary catheterization, anti-stress ulcer prophylaxis and prior antibiotic use will be noted. Presence or absence of nosocomial pneumonia would also be noted daily. Lower respiratory secretions would be obtained by the protected non-bronchoscopic mini-BAL technique in order to identify the causative organisms. All the subjects will be followed up daily until discharge from the ICU or death. Primary outcome variable was the development of nosocomial pneumonia during the ICU stay. Secondary outcome variables were hospital mortality, length of ICU stay. A total of 506 patients will have to be studied (approximately 253 patients in each treatment group). This study will have a statistical power of 75% to detect a 50% reduction in the incidence of nosocomial pneumonia in the intervention group with a 95% level of confidence assuming that incidence of pneumonia in the control group is 16%.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nosocomial Pneumonia, Healthcare-Associated Pneumonia, Aspiration Pneumonia, Ventilator-Associated Pneumonia
Keywords
oropharyngeal cleansing, oral decontamination, oropharyngeal bacterial flora, oropharyngeal colonization, critical illness, mechanical ventilation, tracheal intubation, prophylaxis

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
512 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
Arm Title
2
Arm Type
Active Comparator
Arm Description
Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
Intervention Type
Drug
Intervention Name(s)
Chlorhexidine gluconate
Intervention Description
Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
Intervention Type
Drug
Intervention Name(s)
Potassium permanganate
Intervention Description
Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
Primary Outcome Measure Information:
Title
Development of nosocomial pneumonia
Time Frame
During hospital stay
Secondary Outcome Measure Information:
Title
In-hospital mortality
Time Frame
During hospital stay
Title
Length of ICU stay (days)
Time Frame
Till discharge from ICU or death

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients admitted to the medical intensive care unit and are expected to stay in ICU for > 48 hours Exclusion Criteria: Pregnant women Patients with nosocomial pneumonia at time of ICU admission Patients with community-acquired pneumonia at time of ICU admission Patients in whom oropharyngeal cleansing is contra-indicated
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dilip R Karnad, MD,FACP,FRCP
Organizational Affiliation
Professor of Medicine, K E M Hospital, Parel, Mumbai 400012, India
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical-Neuro Intensive Care Unit, K E M Hospital, Parel
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400012
Country
India

12. IPD Sharing Statement

Citations:
PubMed Identifier
9069004
Citation
Abele-Horn M, Dauber A, Bauernfeind A, Russwurm W, Seyfarth-Metzger I, Gleich P, Ruckdeschel G. Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination (SOD). Intensive Care Med. 1997 Feb;23(2):187-95. doi: 10.1007/s001340050314.
Results Reference
background
PubMed Identifier
8769511
Citation
DeRiso AJ 2nd, Ladowski JS, Dillon TA, Justice JW, Peterson AC. Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest. 1996 Jun;109(6):1556-61. doi: 10.1378/chest.109.6.1556.
Results Reference
background
PubMed Identifier
11089748
Citation
Fourrier F, Cau-Pottier E, Boutigny H, Roussel-Delvallez M, Jourdain M, Chopin C. Effects of dental plaque antiseptic decontamination on bacterial colonization and nosocomial infections in critically ill patients. Intensive Care Med. 2000 Sep;26(9):1239-47. doi: 10.1007/s001340000585.
Results Reference
background
PubMed Identifier
2957488
Citation
Francis JR, Hunter B, Addy M. A comparison of three delivery methods of chlorhexidine in handicapped children. I. Effects on plaque, gingivitis, and toothstaining. J Periodontol. 1987 Jul;58(7):451-5. doi: 10.1902/jop.1987.58.7.451.
Results Reference
background

Learn more about this trial

Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients

We'll reach out to this number within 24 hrs